Loading patent…
AssigneeHoechst Japan Limited
InventorsMizuho Inazu, Ryoichi Satoh, Tsutomu Inoue, Hiroshi Kitagawa, Masakazu Katoh, Heinrich Englert, Denis Carniato, Hans-Jochen Lang
Estimating the term…
Pharmaceutical compositions for the inhibition of bone resorption comprising a pharmaceutical carrier and a therapeutically effective amount of a benzopyran derivative represented by the general formula (I) ##STR1## wherein the broken-lined bond denotes an optional double bond, R.sub.1 denotes a hydrogen atom or a hydroxyl group, R.sub.2 denotes a cyano group, a phenylsulfonyl group or a halogen-substituted methoxyl group, and R.sub.3 denotes a group having the formula ##STR2## Since they inhibit bone resorption, they are useful for the treatment and prevention of diseases associated with bone metabolism.
A method for treating bone resorption which comprises administering an effective amount for said treatment of a benzopyran derivative represented by formula (I) ##STR12## wherein the broken-lined bond denotes an optional double bond, R.sub.1 denotes a hydrogen atom or a hydroxyl group, R.sub.2 denotes a cyano group, a phenylsulfonyl group or a halogen-substituted methoxyl group, and R.sub.3 denotes a group having the formula ##STR13## together with a pharmaceutically acceptable carrier.
The method of claim 4 wherein R.sub.1 denotes a hydroxyl group, R.sub.2 denotes a cyano group, R.sub.3 denotes a 2-oxo-1-pyrrolidinyl group in trans position to R.sub.1, and the broken-lined bond denotes a single bond.
The method of claim 4 wherein R.sub.1 denotes a hydroxyl group, R.sub.2 denotes a phenylsulfonyl group, R.sub.3 denotes a 2-oxo-1-pyrrolidinyl group in trans position to R.sub.1, and the broken-lined bond denotes a single bond.
The method of claim 4, wherein said effective amount is a daily dosage of from 1 to 200 mg for adults.
Dependencies are inferred from the claim text.